EUCTR2008-005424-85-LT进行中（未招募）不适用
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disorder
Wyeth Pharmaceuticals, Inc. Acting through its devision Wyeth Research, a Pfizer Company0 个研究点目标入组 850 人开始时间: 2009年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 850
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Open-Label Phase, Screening/Baseline
- •1.Male or female subjects aged 18 years or older.
- •2.Outpatient status.
- •3.A primary diagnosis of MDD, single or recurrent episode, without psychotic features.
- •4.Depressive symptoms for at least 30 days before the screening visit.
- •5.A HAM-D17 total score =20 at the screening visit.
- •6.A score =2 on item 1 (depressed mood) of the HAM-D17 at the screening visit.
- •7.A score =4 on the Clinical Global Impressions Scale-Severity (CGI-S) at the screening visit.
- •Stability Phase
- •1.Response to treatment, as defined as a HAM-D17 total score of = 11 at the conclusion of the 8-week open-label phase.
- •2.A CGI-I score = 2 at the conclusion of the 8-week open-label phase.
- •Double-Blind Phase
- •1.Maintenance of stability, as defined as a HAM-D17 total score of = 11 at the conclusion of the 12-week stability phase
- •2.CGI-I score = 2 at the conclusion of the 12-week stability phase
- •3.Absence of an assessed HAM-D17 total score of = 16 or CGI-I score of = 4 at any visit during the stability phase..
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Open-Label Phase, Screening
- •1.Treatment with DVS SR at any time in the past.
- •2.Known or suspected allergy to venlafaxine.
- •3.Significant risk of suicide based on clinical judgment.
- •4.HAM-D17 score > 3 on Item 3 (Suicide) at the screening visit.
- •5.Columbia Suicide-Severity Rating Scale (C-SSRS) determination of yes” on question 4 or question 5 for the Suicidal Ideation section at the screening visit.
- •6.Pregnant or breastfeeding women.
- •7.a) Current psychoactive substance abuse or dependence, manic episode, posttraumatic stress disorder, obsessive compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder; b) current generalized anxiety disorder, panic disorder, or social anxiety disorder considered by the investigator to be primary; c) presence of a clinically important personality disorder.
- •8.Depression associated with the presence of an organic mental disorder due to a general medical condition or a neurologic disorder.
- •9.History of seizure disorder other than a single childhood febrile seizure.
- •10.Any major illness/condition.
- •11.History or current evidence of gastrointestinal disease known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs.
- •12.History of neoplastic disorder (within 2 years), with the exception of basal cell or squamous cell carcinoma of the skin.
- •13.Known presence of raised intraocular pressure or history of narrow angle glaucoma.
- •14.Major acute illness within 90 days of the screening visit.
- •15.Myocardial infarction within 180 days of the screening visit.
- •Open-Label Phase, Baseline
- •1.Clinically important abnormalities indicated by electrocardiograms (ECG), vital signs, laboratory tests or urine drug screening.
- •2.HAM-D17 score >3 on Item 3 (Suicide) at the baseline visit.
- •3.Columbia Suicide-Severity Rating Scale (C-SSRS) determination of yes” on question 4 or question 5 for the Suicidal Ideation section at the baseline visit.
研究者
相似试验
进行中（未招募）
不适用
A Clinical Study of the Safety and Efficacy of Natalizumab in Acute Ischemic StrokeAcute Ischemic StrokeMedDRA version: 16.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852EUCTR2013-001514-15-ESBiogen Idec Research Limited200
进行中（未招募）
1 期
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive DisorderThe desvenlafaxine succinate sustained release formulation, DVS SR, is being used in development programs for the treatment of major depressive disorder (MDD).EUCTR2008-005424-85-FRWyeth Research Division of Wyeth Pharmaceuticals Inc.850
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive DisorderThe desvenlafaxine succinate sustained release formulation, DVS SR, is being used in development programs for the treatment of major depressive disorder (MDD).MedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2008-005424-85-FIWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer company850
进行中（未招募）
不适用
A Clinical Study of the Safety and Efficacy of Natalizumab in Acute Ischemic StrokeAcute Ischemic StrokeMedDRA version: 18.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852EUCTR2013-001514-15-DEBiogen Idec Research Limited200
进行中（未招募）
1 期
A Clinical Study of the Safety and Efficacy of Natalizumab in Acute Ischemic StrokeAcute Ischemic StrokeMedDRA version: 20.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852EUCTR2015-004783-11-DEBiogen Idec Research Limited240